Bio Nova International Pty Ltd
Overview
Bio Nova International Pty Ltd produces implantable tissue structures for the treatment of defective tissues and organs. A world leader and pioneer in tissue engineering, Bio Nova has developed methods to grow tissue structures in animals and safely transplant the engineered structures into humans. The technology is already used to produce replacement blood vessels that are exported to many European, Middle Eastern and Asian countries. Current research is targeted at developing a patient-specific coronary artery bypass graft. Other applications, which are at various stages from concept through to initial prototypes, include heart valves, stents, ligaments, hernia repair patches, nerve regeneration tubes, dural patches, bioartificial skin, wound dressings, endovascular grafts, bone grafting materials, surgical sealant, and other constructs to enable grafting of pancreatic islet cells for the treatment of diabetes. Bio Nova’s patented technology for engineering tissues combines synthetic materials with animal and human tissue and cells, and is expected to provide the basis for generating spare parts for many future surgical and therapeutic treatments. Bio Nova has Good Manufacturing Practice (GMP) manufacturing facilities and laboratories and ISO 9001 accreditation.
Main business focus/
Listing by sector:
- Medical Devices - Biological-derived devices
- Cardiovascular
Technology/IP
3 trademarks registered around the world 4 groups of patents worldwide with minor amendments for various regions
Partnering Opportunities
Bio Nova International Pty Ltd is a privately owned company based in Melbourne, Australia.
Bio Nova is a pioneer in tissue engineering with proven capabilities in development and commercialisation of medical devices. The company has established GMP facilities and sells products through its international distribution network.
As a medical device company, Bio Nova benefits from a shorter route to market than drugs which means that the company carries substantially lower risk than most biotechnology companies.
Contact Details
| Contact person | Hugh McCormack |
|---|---|
| Job Title | Chief Executive Officer |
| Address | 36 Munster Terrace |
| City/Suburb | North Melbourne |
| State | Victoria |
| bni@bionova.com.au | |
| Phone | +61 3 9326 6955 |
| Fax | +61 3 9329 8071 |
| Website | http://www.bionova.com.au |
